Post by sakibkhan46 on Feb 20, 2024 7:11:30 GMT 2
To supplement the certification request with information from other production sources in Novavax's global supply chain at a later date. The potential of Novavax and the CoV2373 vaccine to address vaccine access issues. Control the spread and protect the public. and the intended efficacy, safety, and utility of CoV2373 and the expected delivery of the CoV2373 vaccine. They are all forwardlooking statements. Novavax cautions that These forwardlooking statements are subject to a number of risks and uncertainties. This may cause actual results to differ materially from those indicated in the forwardlooking statements. whether expressly or impliedly These risks and uncertainties include: but not limited to Challenges in meeting safety, efficacy, and product characteristics requirements Either by the company itself or in conjunction with a partner.
This includes requirements regarding process validation and analytical Belgium Phone Number method evaluation testing required to meet regulatory requirements; Problems in procuring raw materials and various materials that are currently in short supply; Resource limitations including human capital and production capacity that impact Novavax's ability to proceed on its planned regulatory path; challenges in meeting contractual obligations with private, government and other entities, and other risk factors identified in the “Risk Factors” and “Management's Discussion and Analysis of Financial Condition and Results of Operations” sections.
” in Novavax's Annual Report on Form 10K for the year ended December 31, 2021, as filed with the Securities and Exchange Commission SEC. Investors should not place undue reliance on forwardlooking statements. This press release is too much. We invite investors to read our filings with the SEC at . To study these messages and other risks and uncertainties. The forwardlooking statements in this press release reflect information only as of the date of this release. We undertake no obligation to update or revise these messages. Our business involves many risks and uncertainties. Including those referenced above, investors, those interested in investing. and other parties should carefully
This includes requirements regarding process validation and analytical Belgium Phone Number method evaluation testing required to meet regulatory requirements; Problems in procuring raw materials and various materials that are currently in short supply; Resource limitations including human capital and production capacity that impact Novavax's ability to proceed on its planned regulatory path; challenges in meeting contractual obligations with private, government and other entities, and other risk factors identified in the “Risk Factors” and “Management's Discussion and Analysis of Financial Condition and Results of Operations” sections.
” in Novavax's Annual Report on Form 10K for the year ended December 31, 2021, as filed with the Securities and Exchange Commission SEC. Investors should not place undue reliance on forwardlooking statements. This press release is too much. We invite investors to read our filings with the SEC at . To study these messages and other risks and uncertainties. The forwardlooking statements in this press release reflect information only as of the date of this release. We undertake no obligation to update or revise these messages. Our business involves many risks and uncertainties. Including those referenced above, investors, those interested in investing. and other parties should carefully
